HOME >> BIOLOGY >> NEWS
Study finds that only half of a commonly used cancer drug is activated in cancer patients

NEW ORLEANS, June 8 According to results reported at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO), only half of the delivered dose of a commonly used chemotherapeutic agent may be activated in cancer patients.

The study, presented in a poster discussion session by Jason Fisher, a student at the University of Pittsburgh School of Engineering, analyzed data from 31 cancer patients given 30-minute infusions of gemcitabine to determine what percentage of the drug dose was associated with concentrations that exceeded the body's ability to activate the drug. He found that while approximately 50 percent of the gemcitabine dose was likely to be converted to active metabolites, the other 50 percent was likely to be inactivated, and as a result, possibly not contribute to a therapeutic effect.

"The purpose of this study was to use mathematics and engineering to try to improve cancer therapy," said Robert Parker, Ph.D., assistant professor of chemical engineering at the University of Pittsburgh and Mr. Fisher's undergraduate research project advisor. "We were surprised to find that about half of the dose of the drug administered might not be converted into an active form. The implication is that alternative schedules of gemcitabine infusions need to be evaluated carefully."

Dr. Parker explained that patients received gemcitabine doses of 650-950 mg/square meter and underwent pharmacokinetic sampling. Mathematical models were developed to calculate the time profile of drug concentrations in the body. "Although the study results demonstrate that administering gemcitabine as a 30-minute infusion resulted in approximately half of the dose being inactivated before it could be metabolized, the clinical implications of the data need to be explored further," said Dr. Parker.

The study was conducted on behalf of the Cancer and Leukemia Group B. Co-investigators of the study include Merrill J. Egorin, M.D., professo
'"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
8-Jun-2004


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... YORK (PRWEB) , ... November 19, 2019 , ... The ... Plaza Times Square in New York City. The one-day event will be chaired by ... group of leaders in the space. , “We are witnessing significant innovation in ...
(Date:11/14/2019)... ... November 13, 2019 , ... NDA Partners Chairman ... regulatory affairs and program management executive with more than 33 years of regulatory ... the firm as an Expert Consultant. , Robert Peterson has extensive experience ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... medical devices, today announced the creation of a Global Regulatory Affairs Department, to ... Device industry is that the regulatory element to any Medtech organization is more ...
Breaking Biology News(10 mins):
(Date:12/2/2019)... ... ... Registration is now open for the American Society of Gene & Cell ... May 12-15, 2020, in Boston. The meeting is the premier event in the field ... stakeholders with the goal of advancing gene and cell therapies to alleviate human disease. ...
(Date:11/20/2019)... ... November 20, 2019 , ... ... of about 8,500 microturbine electrical power generation units from 2019-2028. The value of ... over 2017's projection of 3,821 units worth $569 million. , Reference to ...
(Date:11/12/2019)... Wis. (PRWEB) , ... November 12, 2019 , ... ... food ingredient solutions for the food and beverage industry launched a new innovative ... improve the digital experience. Now, the website offers global visitors updated ingredient usage ...
(Date:11/6/2019)... ... ... Diversified Technologies, Inc. has introduced a PEF production system for ... processing. , The DTI Industrial PEF Unit can pre-treat whole pieces of fruits and ... up to 50% and achieve up to an 80% reduction of drying energy. ...
Breaking Biology Technology:
Cached News: